Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia.

TitleVariation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia.
Publication TypeJournal Article
Year of Publication2013
AuthorsFisher BT, Gerber JS, Leckerman KH, Seif AE, Huang YS, Li Y, Harris T, Torp K, Douglas R, Shah A, Walker D, Aplenc R
JournalLeuk Lymphoma
Volume54
Issue8
Pagination1633-9
Date Published2013 Aug
ISSN1029-2403
KeywordsAdolescent, Anti-Bacterial Agents, Child, Child, Preschool, Drug Prescriptions, Female, Hospitals, Pediatric, Humans, Male, Practice Patterns, Physicians', Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, United States
Abstract

Antibiotic variation among pediatric oncology patients has not been well-described. Identification of significant variability in antibiotic use within this population would warrant evaluation of its clinical impact. We conducted a retrospective cohort study of newly diagnosed patients with pediatric acute lymophoblastic leukemia (ALL) hospitalized from 1999 to 2009 in 39 freestanding US children's hospitals within the Pediatric Health Information System. Medication use data were obtained for the first 30 days from each patient's index ALL admission date. Antibiotic exposure rates were reported as antibiotic days/1000 hospital days. Unadjusted composite broad-spectrum antibiotic exposure rates varied from 577 to 1628 antibiotic days/1000 hospital days. This wide range of antibiotic exposure was unaffected by adjustment for age, gender, race and days of severe illness (adjusted range: 532-1635 days of antibiotic therapy/1000 hospital days). Antibiotic use for children with newly diagnosed ALL varies widely across children's hospitals and is not explained by demographics or illness severity.

DOI10.3109/10428194.2012.750722
Alternate JournalLeuk. Lymphoma
PubMed ID23163631
PubMed Central IDPMC3906846
Grant ListP30 CA016520 / CA / NCI NIH HHS / United States
R01 CA133881 / CA / NCI NIH HHS / United States
R01 CA133881-01 / CA / NCI NIH HHS / United States